Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
2.

In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules.

Willy JA, Schulte NE, Kreklau EL, Walgren JL, Renninger ML, Baker TK.

Toxicol Sci. 2016 Jun;151(2):302-11. doi: 10.1093/toxsci/kfw050. Epub 2016 Mar 11.

PMID:
26969369
3.

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM, Iversen PW, Meier TI, Foreman RT, Zeckner D, Sissons SE, Halstead BW, Lin AB, Donoho GP, Qian Y, Li S, Wu S, Aggarwal A, Ye XS, Starling JJ, Gaynor RB, de Dios A, Du J.

Mol Cancer Ther. 2014 Jun;13(6):1442-56. doi: 10.1158/1535-7163.MCT-13-0849. Epub 2014 Mar 31.

4.

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.

Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP.

Blood Cancer J. 2013 Apr 12;3:e109. doi: 10.1038/bcj.2013.6.

7.

In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations.

Pollok KE, Hartwell JR, Braber A, Cooper RJ, Jansen M, Ragg S, Bailey BJ, Erickson LC, Kreklau EL, Williams DA.

Hum Gene Ther. 2003 Dec 10;14(18):1703-14.

PMID:
14670122
8.

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J.

Br J Cancer. 2003 Oct 20;89(8):1517-23.

9.
11.
13.

Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.

Kreklau EL, Kurpad C, Williams DA, Erickson LC.

J Pharmacol Exp Ther. 1999 Dec;291(3):1269-75.

PMID:
10565851
14.

Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation.

Kreklau EL, Carlson EJ, Drewett JG.

Mol Cell Endocrinol. 1999 Jul 20;153(1-2):103-11.

PMID:
10459858

Supplemental Content

Loading ...
Support Center